Brief: Palatin Initiates Phase 2 Clinical Study Of Bremelanotide For The Treatment Of Obesity
12/06/2024 13:09
June 12 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN INITIATES PHASE 2 CLINICAL STUDY OF BREMELANOTIDE
FOR
THE TREATMENT OF OBESITY
* PALATIN TECHNOLOGIES INC: TOPLINE DATA EXPECTED BY END OF
CALENDAR YEAR 2024
* PALATIN TECHNOLOGIES: ADDITIONAL STUDIES UNDER ASSESSMENT
FOR
MULTIPLE METABOLIC CONDITIONS
Source text for Eikon: ID:nPn3q7C9Ba
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity